



20 APR 2009

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Bayer Pharmaceuticals Corp.
400 Morgan Lane
West Haven, CT 06516

In re Application of WOLTERING et al.
Application No.: 10/586,023
PCT No.: PCT/EP04/14871
Int. Filing: 31 December 2004
Priority Date: 14 January 2004
Attorney Docket No.: BHC 031067
For: TRICYCLIC BENZAZEPINE
DERIVATIVES AS SQUALENE SYNTHASE
INHIBITORS USED FOR THE TREATMENT OF
CARDIO VASCULAR DISEASES

DECISION ON
PETITION TO REVIVE
UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 17 February 2009 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b).

A review of the application file reveals that a declaration, in compliance with 37 CFR 1.497(a) and (b), has now been provided. The required petition fee of \$1640 was also paid. Thus, the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being forwarded to the United States Designated/Elected Office for further processing. The 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) date is 17 February 2009.

Cynthia M. Kratz
Attorney Advisor
PCT Legal Office
Office of PCT Legal Administration
Telephone: (571) 272-3286
Facsimile: (571) 273-0459